Olivier Danos - Feb 1, 2025 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Role
Chief Scientific Officer
Signature
/s/ Patrick J. Christmas as attorney-in-fact
Stock symbol
RGNX
Transactions as of
Feb 1, 2025
Transactions value $
-$43,998
Form type
4
Date filed
4/4/2025, 05:16 PM
Previous filing
Jan 6, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGNX Common Stock Tax liability -$44K -5.45K -2.35% $8.07 226K Feb 1, 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Olivier Danos is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on August 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on February 1, 2025.